Carl Hansen, AbCellera CEO

Ab­Cellera and Cana­da to in­vest $500M+ to boost an­ti­body man­u­fac­tur­ing and re­search

Ab­Cellera, a Van­cou­ver-based an­ti­body man­u­fac­tur­er, re­ceived an in­vest­ment from the gov­ern­ment of Cana­da and the province of British Co­lum­bia.

The in­vest­ment will to­tal CA$701 mil­lion ($515.9 mil­lion) over the next eight years, with the fund­ing go­ing to­ward build­ing new in­fra­struc­ture to de­vel­op an­ti­body-based med­i­cines. This in­cludes a site to de­vel­op and man­u­fac­ture an­ti­body med­i­cines through the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.